Company

PulseSight Therapeutics

PulseSight Therapeutics develops gene therapies for retinal diseases such as wet and dry age-related macular degeneration.

About

PulseSight Therapeutics develops non-viral gene therapies for retinal diseases using an electro-transfection delivery device. Its pipeline includes PST-809 for wet AMD and PST-611 for dry AMD/geographic atrophy. Based in France, it raised Seed funding in February 2024, co-led by +ND Capital, BB Pureos Bioventures, and Korea Investment Partners.

2Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in